Navigation Links
Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
Date:4/21/2009

Presently No Approved Treatments

MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the disease.

"Today's announcement marks the achievement of yet another important milestone in the development of Arikace for chronic lung infections," said Tim Whitten, Transave's Chief Executive Officer. "We believe Arikace has the potential to be an important new treatment for non-CF patients with bronchiectasis. We look forward to seeing the Phase II results in June and moving to Phase III as soon as possible."

The double-blind, placebo-controlled study is designed to evaluate Arikace in non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the trial, 64 adult patients were randomized 2:1 to Arikace - either a 280 mg or a 560 mg dose - or placebo for 28 days, followed by a 28-day off-treatment observation period. Arikace and placebo are administered once daily using an Investigational eFlow(R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient, portable aerosol delivery system. Sixteen clinical sites throughout Europe and India are participating in the study.

Bronchiectasis is characterized by localized, irreversible enlargement of the bronchial tubes. Involved bronchi are dilated, inflamed, and easily collapsible, resulting in airflow obstruction and impaired clearance of secretions. The accumulation of mucus in the bronchi leads to frequent infections, which further reduce lung function in these patients. One of the m
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 UT Southwestern Medical ... selectively and irreversibly interferes with the activity of ... of tumors. , The molecule, SML-8-73-1 (SML), interferes ... viral oncogene homolog. The gene produces proteins called ... K-Ras can result in normal cells dividing uncontrollably ...
(Date:7/28/2014)... 28, 2014 Lourdes Health System has ... and reduced wait times for veterans needing medical care. ... in the state—and the only one in Camden, Burlington ... Community Care program (PC3). PC3 gives veterans access to ... cannot provide services due to lack of available specialists, ...
(Date:7/28/2014)... July 28, 2014 The report, ... & Geography - Trends and Forecasts to 2019” ... with analysis and forecasting of the global consumption ... market data tables with 39 figures spread through ... Market"., http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are ...
(Date:7/28/2014)... 28, 2014 The American ... of professionals engaged in the field of organ ... Transplantation and Immunology Research Network (TIRN), a ... research. As modern organ transplantation continues to diversify, ... could provide more opportunities for physicians, scientists and ...
(Date:7/28/2014)... with one of the UK,s most common respiratory diseases ... pulmonary disease (COPD) is the name for a collection ... damage to the lungs. Often linked to smoking, ... hospital admissions in the UK, with a high proportion ... discharged. , A team of researchers, led ...
Breaking Medicine News(10 mins):Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3
... Children,s Research Hospital investigators have found that an electrically ... is critical to the acute hearing of humans and ... how hearing loss can result from malfunction of this ... drugs such as aspirin. , Sound entering the cochlea ...
... $12 Million in Series A First Tranche Financing, ... Capital announced,today the formation of ACT Biotech Inc., a ... drugs. ACT Biotech has,entered into a license agreement with ... stage oncology assets. In conjunction with the,agreement, ACT has ...
... Reality, MANHATTAN BEACH, Calif., May 7 A ... 2006 continues,today with open hearings and fact-finding in California. ... how homecare and nursing home,workers in the long term ... greatest strength to win for their families and the,clients ...
... MECHANICSBURG, Pa., May 7 Select Medical Corporation,will release ... 31,2008 on Thursday, May 15, 2008., The Company ... on Wednesday, May 21, 2008, at 11:00am EDT. The ... international dial in number is,1-210-839-8503. The passcode for the ...
... neural development, mouse study shows , , WEDNESDAY, May 7 ... that suppresses appetite by blocking cannabinoid receptors in the ... scientists report. , In research with mice, they found ... of the brain necessary for neural development in young ...
... may increase adults risk for having dementia, according to ... Health. Their analysis of published obesity and dementia ... a consistent relationship between the two diseases. The results ... of Obesity in the May, 2008 issue of Obesity ...
Cached Medicine News:Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 2Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 3Health News:ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare 2Health News:Open Hearings, Fact-Finding Today by SEIU Long Term Care Workers Continues Democratic Process Begun in 2006 2Health News:Obesity linked to increased risk for dementia 2
(Date:7/25/2014)... , July 25, 2014  Corporate libraries are ... understanding new advancements in technology and how to cope ... libraries in the pharmaceutical and medical device industries are ... the information and services they provide. ... LLC there are many forces of change that leading ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook to ... Endoscopy Systems market. The report provides value, in millions ... (in US dollars) within market segments: Photo ... Endoscopes , Capsule Endoscopy Data Recorders , ... provides company shares and distribution shares data for each ...
(Date:7/25/2014)...  Smile Train and its technology partner BioDigital have ... Simulator among leading global health innovations in The Hive ... Washington, D.C. at The John F. ... "Smile Train is honored to be represented through our ... in health and medicine that TEDMED unites each year," ...
Breaking Medicine Technology:Forces of Change Reshaping Corporate Libraries & Information Services 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: